Oruka Therapeutics reports Q4 EPS (49c), consensus (98c)

“We made tremendous progress in our first year as a company, including our successful public debut, raising over $475 million to fund the company through 2027, and advancing ORKA-001 into the clinic,” said Lawrence Klein, CEO of Oruka. “As we move into 2025, we are excited about the momentum ahead, with our first clinical data readout anticipated later this year as well as our plans to advance ORKA-002 into the clinic and ORKA-001 into Phase 2 development. Looking forward, we expect to deliver a clinical catalyst every six months, which could progressively establish ORKA-001 and ORKA-002 as the best treatment options in the incredibly important therapeutic area of psoriatic disease.”